Cordoba, Argentina

Instituto Medico Strusberg

Rheumatoid Arthritis

Musculoskeletal Diseases

Arthritis

Overweight

Ankylosing Spondylitis

Connective Tissue Diseases

Vitiligo

Joint Diseases

Autoimmune Diseases

Rheumatic Diseases

MK-6194-007

Peresolimab

Tirzepatide

MK-6194

Upadacitinib

LY3298176

Lilly

AbbVie

Merck Sharp & Dohme (MSD)

condition

Obesity

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Instituto Medico Strusberg | Cordoba, Argentina

Site insights

Work at this site?

Active trials

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

Trial sponsors